antiplatelets drug

A EFFACER - Aspirin - Atopaxar - Cangrelor - Clopidogrel - Dipyridamol - Elinogrel - Prasugrel - Sulfinpyrazone - Ticagrelor - Ticlopidine - Triflusal - Vorapaxar      

pathologytreatmentpatient Demonstrated benefit and harm k      
acute coronary syndromeaspirinnot classified

versus placebo or control

No demonstrated result for efficacy

14 trialsmeta-analysis
acute coronary syndromeatopaxarnot classified

versus placebo or control

No demonstrated result for efficacy

2 trialsmeta-analysis
acute coronary syndromeclopidogrelnot classified

versus placebo or control

No demonstrated result for efficacy

2 trialsmeta-analysis
acute coronary syndromeclopidogrelnot classified

versus aspirin

No demonstrated result for efficacy

clopidogrel + aspirin inferior to aspirin in terms of Major bleeds in CURE, 2001

1 trialmeta-analysis
acute coronary syndromeclopidogrelnot classified

versus clopidogrel

No demonstrated result for efficacy

clopidogrel high-dose regimen inferior to clopidogrel standard-dose in terms of Major bleeds in CURRENT OASIS 7 (clopidogrel), 2010

1 trialmeta-analysis
acute coronary syndromedipyridamolnot classified

versus placebo or control

No demonstrated result for efficacy

1 trialmeta-analysis
acute coronary syndromeelinogrelnot classified

versus placebo or control

No demonstrated result for efficacy

1 trialmeta-analysis
acute coronary syndromeprasugrelnot classified

versus clopidogrel

No demonstrated result for efficacy

prasugrel inferior to clopidogrel in terms of all bleeding (major and minor) in TRITON-TIMI 38, 2007

prasugrel inferior to clopidogrel in terms of Major bleeds in TRITON-TIMI 38, 2007

prasugrel inferior to clopidogrel in terms of fatal bleeding in TRITON-TIMI 38, 2007

2 trialsmeta-analysis
acute coronary syndromesulfinpyrazonenot classified

versus placebo or control

No demonstrated result for efficacy

4 trialsmeta-analysis
acute coronary syndrometicagrelornot classified

versus clopidogrel

No demonstrated result for efficacy

2 trialsmeta-analysis
acute coronary syndrometiclopidinenot classified

versus placebo or control

No demonstrated result for efficacy

3 trialsmeta-analysis
acute coronary syndrometrapidilnot classified

versus placebo or control

No demonstrated result for efficacy

1 trialmeta-analysis
acute coronary syndrometriflusalnot classified

versus placebo or control

No demonstrated result for efficacy

1 trialmeta-analysis
acute coronary syndromevorapaxarnot classified

versus placebo or control

No demonstrated result for efficacy

1 trialmeta-analysis
acute myocardial infarctionaspirinnot classified

versus placebo or control

No demonstrated result for efficacy

6 trialsmeta-analysis
acute myocardial infarctionclopidogrelnot classified

versus placebo or control

No demonstrated result for efficacy

2 trialsmeta-analysis
acute myocardial infarctionelinogrelnot classified

versus placebo or control

No demonstrated result for efficacy

1 trialmeta-analysis
acute myocardial infarctionsulfinpyrazonenot classified

versus placebo or control

No demonstrated result for efficacy

3 trialsmeta-analysis
acute myocardial infarctionticlopidinenot classified

versus placebo or control

No demonstrated result for efficacy

1 trialmeta-analysis
CABG surgeryaspirinnot classified

versus placebo or control

No demonstrated result for efficacy

5 trialsmeta-analysis
CABG surgeryclopidogrelnot classified

versus

No demonstrated result for efficacy

1 trialmeta-analysis
CABG surgerydipyridamolnot classified

versus

No demonstrated result for efficacy

1 trialmeta-analysis
CABG surgerydipyridamolnot classified

versus placebo or control

No demonstrated result for efficacy

12 trialsmeta-analysis
CABG surgerysulfinpyrazonenot classified

versus placebo or control

No demonstrated result for efficacy

1 trialmeta-analysis
CABG surgerysulotrobannot classified

versus placebo or control

No demonstrated result for efficacy

1 trialmeta-analysis
CABG surgeryticlopidinenot classified

versus placebo or control

No demonstrated result for efficacy

6 trialsmeta-analysis
cardiovascular preventionaspirinnot classified

versus

No demonstrated result for efficacy

aspirin inferior to placebo in terms of major bleeding in ASCEND, 2018

2 trialsmeta-analysis
cardiovascular preventionaspirinnot classified

versus placebo or control

No demonstrated result for efficacy

aspirin inferior to placebo in terms of non fatal MI in DAMAD, 1989

21 trialsmeta-analysis
cardiovascular preventionaspirinprimary prevention

versus placebo or control

No demonstrated result for efficacy

aspirin inferior to placebo in terms of Major gastrointestinal bleeding in Physicians Health Study, 1989 (primary prevention patients)

aspirin inferior to placebo in terms of Major extracranial bleed in HOT, 1998 (primary prevention patients)

aspirin inferior to placebo in terms of Gastrointestinal Bleeding in HOT, 1998 (primary prevention patients)

aspirin inferior to placebo in terms of Major gastrointestinal bleeding in HOT, 1998 (primary prevention patients)

aspirin inferior to no treatment in terms of Gastrointestinal Bleeding in Primary Prevention Project, 2001 (primary prevention patients)

aspirin inferior to placebo in terms of Gastrointestinal Bleeding in Women’s Health Study, 2005 (primary prevention patients)

aspirin inferior to placebo in terms of Peptic ulcer in Women’s Health Study, 2005 (primary prevention patients)

aspirin inferior to placebo in terms of Hematuria in Women’s Health Study, 2005 (primary prevention patients)

aspirin inferior to placebo in terms of Major gastrointestinal bleeding in Women’s Health Study, 2005 (primary prevention patients)

6 trialsmeta-analysis
cardiovascular preventionaspirinsecondary prevention

versus placebo or control

No demonstrated result for efficacy

1 trialmeta-analysis
cardiovascular preventionclopidogrelnot classified

versus aspirin

No demonstrated result for efficacy

2 trialsmeta-analysis
cardiovascular preventionclopidogrelsecondary prevention

versus aspirin

No demonstrated result for efficacy

1 trialmeta-analysis
cardiovascular preventionclopidogrelsecondary prevention

versus placebo or control

No demonstrated result for efficacy

clopidogrel inferior to placebo (on top aspirin) in terms of moderate bleeding in CHARISMA, 2006 (secondary prevention patients)

1 trialmeta-analysis
cardiovascular preventiondipyridamolnot classified

versus placebo or control

No demonstrated result for efficacy

15 trialsmeta-analysis
cardiovascular preventiondipyridamolnot classified

versus aspirin

No demonstrated result for efficacy

1 trialmeta-analysis
cardiovascular preventionketanserinenot classified

versus placebo or control

No demonstrated result for efficacy

3 trialsmeta-analysis
cardiovascular preventionpicotamidenot classified

versus placebo or control

No demonstrated result for efficacy

4 trialsmeta-analysis
cardiovascular preventionsulfinpyrazonenot classified

versus placebo or control

No demonstrated result for efficacy

1 trialmeta-analysis
cardiovascular preventionsuloctidilnot classified

versus placebo or control

No demonstrated result for efficacy

4 trialsmeta-analysis
cardiovascular preventionticagrelornot classified

versus

No demonstrated result for efficacy

1 trialmeta-analysis
cardiovascular preventionticagrelorsecondary prevention

versus placebo or control

No demonstrated result for efficacy

ticagrelor inferior to placebo (on top aspirin) in terms of Major hemorrhage in PEGASUS 60mg, 2015 (secondary prevention patients)

ticagrelor inferior to placebo (on top aspirin) in terms of Major hemorrhage in PEGASUS 90mg, 2015 (secondary prevention patients)

2 trialsmeta-analysis
cardiovascular preventionticlopidinenot classified

versus placebo or control

No demonstrated result for efficacy

17 trialsmeta-analysis
cardiovascular preventionvariousnot classified

versus placebo or control

No demonstrated result for efficacy

1 trialmeta-analysis
cardiovascular preventionvorapaxarsecondary prevention

versus placebo or control

No demonstrated result for efficacy

vorapaxar inferior to placebo (on top aspirin) in terms of major haemorrhage requiring admission to hospital in TRA-2P TIMI 50, 2012 (secondary prevention patients)

vorapaxar inferior to placebo (on top aspirin) in terms of Major hemorrhage in TRA-2P TIMI 50, 2012 (secondary prevention patients)

vorapaxar inferior to placebo (on top aspirin) in terms of Intracranial haemorrhage in TRA-2P TIMI 50, 2012 (secondary prevention patients)

vorapaxar inferior to placebo (on top aspirin) in terms of Major hemorrhage in TRA-2P TIMI 50 (MI subgroup), 2012 (secondary prevention patients)

3 trialsmeta-analysis
diabetes type 2aspirinnot classified

versus placebo or control

No demonstrated result for efficacy

aspirin inferior to placebo in terms of non fatal MI in DAMAD, 1989

7 trialsmeta-analysis
diabetes type 2picotamidenot classified

versus placebo or control

No demonstrated result for efficacy

1 trialmeta-analysis
diabetes type 2sulfinpyrazonenot classified

versus placebo or control

No demonstrated result for efficacy

1 trialmeta-analysis
diabetes type 2ticlopidinenot classified

versus placebo or control

No demonstrated result for efficacy

5 trialsmeta-analysis
hypertensionaspirinprimary prevention

versus placebo or control

No demonstrated result for efficacy

aspirin inferior to placebo in terms of Major extracranial bleed in HOT, 1998 (primary prevention patients)

aspirin inferior to placebo in terms of Gastrointestinal Bleeding in HOT, 1998 (primary prevention patients)

aspirin inferior to placebo in terms of Major gastrointestinal bleeding in HOT, 1998 (primary prevention patients)

1 trialmeta-analysis
percutaneous coronary interventioncilostazolnot classified

versus antiplatelet drugs

No demonstrated result for efficacy

7 trialsmeta-analysis
percutaneous coronary interventionclopidogrelnot classified

versus

No demonstrated result for efficacy

1 trialmeta-analysis
percutaneous coronary interventionclopidogrelnot classified

versus antiplatelet drugs

No demonstrated result for efficacy

4 trialsmeta-analysis
percutaneous coronary interventionclopidogrelnot classified

versus standard clopidogrel

No demonstrated result for efficacy

1 trialmeta-analysis
percutaneous coronary interventionticlopidinenot classified

versus anticoagulant + antiplatelet

No demonstrated result for efficacy

5 trialsmeta-analysis
percutaneous coronary interventionticlopidinenot classified

versus antiplatelet drugs

No demonstrated result for efficacy

2 trialsmeta-analysis
peripheral vascular diseasesaspirinnot classified

versus placebo or control

No demonstrated result for efficacy

5 trialsmeta-analysis
peripheral vascular diseasesclopidogrelnot classified

versus aspirin

No demonstrated result for efficacy

1 trialmeta-analysis
peripheral vascular diseasesdipyridamolnot classified

versus placebo or control

No demonstrated result for efficacy

3 trialsmeta-analysis
peripheral vascular diseasesketanserinenot classified

versus placebo or control

No demonstrated result for efficacy

3 trialsmeta-analysis
peripheral vascular diseasespicotamidenot classified

versus placebo or control

No demonstrated result for efficacy

3 trialsmeta-analysis
peripheral vascular diseasessuloctidilnot classified

versus placebo or control

No demonstrated result for efficacy

4 trialsmeta-analysis
peripheral vascular diseasesticagrelornot classified

versus

No demonstrated result for efficacy

1 trialmeta-analysis
peripheral vascular diseasesticlopidinenot classified

versus placebo or control

No demonstrated result for efficacy

11 trialsmeta-analysis
peripheral vascular diseasesvariousnot classified

versus placebo or control

No demonstrated result for efficacy

1 trialmeta-analysis
post myocardial infarctionaspirinnot classified

versus placebo or control

No demonstrated result for efficacy

8 trialsmeta-analysis
post myocardial infarctionclopidogrelnot classified

versus aspirin

No demonstrated result for efficacy

1 trialmeta-analysis
post myocardial infarctiondipyridamolnot classified

versus placebo or control

No demonstrated result for efficacy

2 trialsmeta-analysis
post myocardial infarctiondipyridamolnot classified

versus aspirin

No demonstrated result for efficacy

1 trialmeta-analysis
post myocardial infarctionticagrelorsecondary prevention

versus placebo or control

No demonstrated result for efficacy

ticagrelor inferior to placebo (on top aspirin) in terms of Major hemorrhage in PEGASUS 60mg, 2015 (secondary prevention patients)

ticagrelor inferior to placebo (on top aspirin) in terms of Major hemorrhage in PEGASUS 90mg, 2015 (secondary prevention patients)

2 trialsmeta-analysis
post myocardial infarctionvorapaxarsecondary prevention

versus placebo or control

No demonstrated result for efficacy

vorapaxar inferior to placebo (on top aspirin) in terms of major haemorrhage requiring admission to hospital in TRA-2P TIMI 50, 2012 (secondary prevention patients)

vorapaxar inferior to placebo (on top aspirin) in terms of Major hemorrhage in TRA-2P TIMI 50, 2012 (secondary prevention patients)

vorapaxar inferior to placebo (on top aspirin) in terms of Intracranial haemorrhage in TRA-2P TIMI 50, 2012 (secondary prevention patients)

1 trialmeta-analysis
post strokeaspirinnot classified

versus placebo or control

No demonstrated result for efficacy

12 trialsmeta-analysis